lenalidomide has been researched along with Thromboembolism in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 3 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Salihoglu, A; Soysal, T; Yilmaz, U | 1 |
| Binder, M; Buadi, FK; Charalampous, C; Dingli, D; Dispenzieri, A; Fonder, AL; Gertz, MA; Goel, U; Gonsalves, W; Hayman, SR; Hobbs, MA; Hwa, YL; Kapoor, P; Kourelis, T; Kumar, S; Kyle, RA; Lacy, MQ; Leung, N; Lin, Y; Rajkumar, SV; Warsame, R | 1 |
| Garcia, DA; Li, A; Li, S; Libby, EN; Lyman, GH; Warnick, G; Wu, Q | 1 |
| Chang, S; Maharaj, S; Seegobin, K; Serrano-Santiago, I; Zuberi, L | 1 |
| Johnson, PRE; Mathur, A; Roddie, PH; Storrar, NPF | 1 |
| Hahn-Ast, C; Kanz, L; Oehrlein, K; Rendl, C; Weisel, K; Zago, M | 1 |
| Andersson, BS; Berenson, JR; Champlin, RE; Chang, VT; Guan, X; Qazilbash, MH; Shen, Y; Wang, J; Wang, ML; Wang, Y; Yang, F; Zhang, W | 1 |
| Cornell, RF; Gailani, D; Garcia, D; Laubach, J; Li, W; Maglio, ME; Moslehi, J; Richardson, PG | 1 |
| Dimopoulos, MA; Kastritis, E; Rajkumar, SV | 1 |
| Goldschmidt, H; Hegenbart, U; Hillengass, J; Ho, AD; Hundemer, M; Klein, U; Kosely, F; Moehler, T; Neben, K; Schmitt, S | 1 |
| Fricker, J | 1 |
| Gajra, A; Singh, A | 1 |
| Haan, J; Molendijk, WJ; Tannemaat, MR; Vries, EP | 1 |
| Barlogie, B; Crowley, J; Durie, BG; Hussein, MA; McCoy, J; Zonder, JA | 1 |
| Boccadoro, M; Palumbo, A; Rodeghiero, F; Rus, C; Zeldis, JB | 1 |
| Angelotta, C; Bennett, CL; Evens, AM; Raisch, DW; Richardson, P; Yarnold, PR; Zonder, JA | 1 |
| Tariman, JD | 1 |
| Wiley, KE | 1 |
9 review(s) available for lenalidomide and Thromboembolism
| Article | Year |
|---|---|
An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunotherapy; Lenalidomide; Lymphoma, Follicular; Rituximab; Thromboembolism | 2021 |
Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Risk; Risk Assessment; Thalidomide; Thromboembolism | 2017 |
Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
Topics: Disease-Free Survival; Humans; Immunosuppressive Agents; Infections; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Neoplasms, Second Primary; Neutropenia; Peripheral Nervous System Diseases; Randomized Controlled Trials as Topic; Risk; Severity of Illness Index; Survival Analysis; Survival Rate; Thalidomide; Thromboembolism | 2016 |
Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Risk Factors; Thalidomide; Thromboembolism; Thrombosis | 2017 |
Treatment of plasma cell dyscrasias with lenalidomide.
Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Paraproteinemias; Pyrazines; Renal Insufficiency; Thalidomide; Thromboembolism; Waldenstrom Macroglobulinemia | 2008 |
Thromboembolism with immunomodulatory agents in the treatment of multiple myeloma.
Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide; Thromboembolism; Warfarin | 2011 |
Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.
Topics: Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasms; Thalidomide; Thromboembolism | 2006 |
Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma.
Topics: Anorexia; Antineoplastic Agents; Apoptosis; Constipation; Diarrhea; Drug Eruptions; Drug Monitoring; Dyspnea; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Nurse's Role; Nursing Assessment; Oncology Nursing; Thalidomide; Thrombocytopenia; Thromboembolism; Treatment Failure | 2007 |
Multiple myeloma and treatment-related thromboembolism: oncology nurses' role in prevention, assessment, and diagnosis.
Topics: Antineoplastic Agents; Drug Monitoring; Early Diagnosis; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Compliance; Primary Prevention; Risk Factors; Thalidomide; Thromboembolism | 2007 |
1 trial(s) available for lenalidomide and Thromboembolism
| Article | Year |
|---|---|
The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma.
Topics: Aged; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Registries; Retrospective Studies; Thalidomide; Thromboembolism | 2020 |
8 other study(ies) available for lenalidomide and Thromboembolism
| Article | Year |
|---|---|
Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Multiple Myeloma; Thromboembolism; Thrombosis | 2023 |
Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Hemorrhage; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazoles; Pyridones; Thalidomide; Thromboembolism; Thrombophilia | 2019 |
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Disease Progression; Drug Evaluation; Feasibility Studies; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Sensation Disorders; Thalidomide; Thromboembolism; Transplantation, Autologous | 2014 |
Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Glucocorticoids; Heparin, Low-Molecular-Weight; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Retrospective Studies; Risk Factors; Thalidomide; Thromboembolism | 2009 |
50th ASH Annual Meeting.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Nadroparin; Rituximab; Thalidomide; Thromboembolism; Uric Acid | 2009 |
Fatal ischemic stroke in a patient receiving lenalidomide for multiple myeloma.
Topics: Anticoagulants; Antineoplastic Agents; Coma; Fatal Outcome; Female; Heparin, Low-Molecular-Weight; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Stroke; Thalidomide; Thromboembolism; Tomography, X-Ray Computed | 2011 |
Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspirin; Dexamethasone; Fibrinolytic Agents; Humans; Lenalidomide; Multiple Myeloma; Risk Factors; Thalidomide; Thromboembolism; Thrombosis; Treatment Outcome | 2006 |
Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Enoxaparin; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recurrence; Risk; Thalidomide; Thromboembolism; Time Factors | 2006 |